Evidence map›Paper›PMID 20336133›Full record

ReviewNature2010

Lessons on longevity from budding yeast.

Matt Kaeberlein

Erratum issuedAbstract readReview
In one paragraph

Review in Nature, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 239 papers.

0numbers the graph read from it
0cells of the map it votes in
239citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

239 citing papers in PubMed.

  1. TPI and GAPDH Interact with Rad9, Linking Glycolytic Enzymes to Cancer.International journal of molecular sciences · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Engineering chronological lifespan toward a robust yeast cell factory.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Review
  8. Article
  9. Biomolecules · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Antioxidants (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

179 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

1 author.

Matt KaeberleinDepartment of Pathology, University of Washington, Seattle, Washington 98195, USA. kaeber@u.washington.edu

Funding

University of Washington Nathan Shock Center of Excellence in the Basic Biology of AgingP30AG013280 · NIA · UNIVERSITY OF WASHINGTON · PI Su-In Lee · 1995 to 2026
$27.1M
Large-Scale quantitative analysis of chronological aging in yeastR21AG031965 · NIA · UNIVERSITY OF WASHINGTON · PI KAEBERLEIN, MATT · 2008 to 2009
$330k
NIA NIH HHS P30 AG013280NIA NIH HHS P30AG013280NIA NIH HHS R21 AG031965NIA NIH HHS R21AG031965
6 · The paper itself

Abstract

The past decade has seen fundamental advances in our understanding of the ageing process and raised optimism that interventions to slow ageing may be on the horizon. Studies of budding yeast have made immense contributions to this progress. Yeast longevity factors have now been shown to modulate ageing in invertebrate and mammalian models, and studies of yeast have resulted in some of the best candidates for anti-ageing drugs currently in development. The first interventions to slow human ageing may spring from the humble yeast.

Indexed as

AgingAnimalsHumansIntracellular Signaling Peptides and ProteinsLongevityNutritional Physiological PhenomenaProtein BiosynthesisProtein Serine-Threonine KinasesSaccharomyces cerevisiaeSirtuinsTOR Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsMTOR protein, humanProtein Serine-Threonine KinasesSirtuinsTOR Serine-Threonine Kinases

Identifiers

PMID20336133
PMCPMC3696189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.